On January 3, 2022 Immix Biopharma (NASDAQ:IMMX) has jumped ~56.7% in the pre-market on above average volume after the company reported that the FDA granted the Rare Pediatric Disease (RPD) designation for IMX-110, a cancer candidate targeted at children (Press release, Immix Biopharma, JAN 3, 2022, View Source [SID1234598017]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

– FDA’s RPD for IMX-110 relates to rhabdomyosarcoma, a potentially fatal form of pediatric cancer in children, and the experimental therapy is currently undergoing a Phase 1b/2a clinical trial.

– In awarding RPD, the federal agency picks drug candidates targeted at serious and life-threatening diseases affecting less than 200K individuals in the U.S. with a primary impact on children aged 18 years or younger.

– If the drugs with the RPD wins approval from the FDA, the sponsor of its marketing application is entitled to receive a Priority Review Voucher (PRV) from the regulator. The PRV can be redeemed to receive priority review for any subsequent marketing application, or it can be sold or transferred.

– The latest regulatory triumph for Immix (IMMX) comes less than a month since its IPO.